Replicel Life Science Ord Stock News

After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration

Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC / ACCESSWI

Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufactur

Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /

Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options  VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2), (�

Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by M

Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Li

Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3, 20

MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (

VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- RepliCel Life Sciences Inc. (OTC PK : REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-gener